# To Demonstrate Equivalent Pharmacokinetic Properties of HD204 and Bevacizumab (Avastin®) in Healthy Male Subjects

> **NCT03390673** · PHASE1 · COMPLETED · sponsor: **Prestige Biopharma Limited** · enrollment: 119 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** HD204
- **DRUG:** Avastin

## Key facts

- **NCT ID:** NCT03390673
- **Lead sponsor:** Prestige Biopharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-19
- **Primary completion:** 2019-03-13
- **Final completion:** 2019-03-13
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2024-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03390673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03390673, "To Demonstrate Equivalent Pharmacokinetic Properties of HD204 and Bevacizumab (Avastin®) in Healthy Male Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03390673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*